FzioMed, Inc. News

FzioMed Announces 500,000 Units of Oxiplex® Shipped Worldwide

SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--FzioMed, Inc. a leading biomaterials company, is pleased to announce that Oxiplex sales have now passed the 500,000 unit mark. Oxiplex is approved outside the United States in more than 70 countries and distributed under various brand names; including, Oxiplex, Oxiplex/SP, MediShield, and Interpose. Oxiplex is an absorbable gel applied to …

Read More

FzioMed Receives FDA Approval for Small Confirmatory Study of Oxiplex® in Patients Undergoing Lumbar Surgery for Disc Herniation

Confirmatory Clinical Study to Support the Effectiveness and Safety of Oxiplex® for the Reduction of Pain and Symptoms Following Lumbar Surgery. SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--FzioMed, Inc., a biomaterials company celebrating 21 years in business, has received approval from FDA to conduct a small confirmatory study of Oxiplex® in the United States. Oxiplex® is an …

Read More

FzioMed Patent US 9,636,434, May 2,2017

COMPOSITIONS OF CARBOXYMETHYLCELLULOSE AND POLYETHYLENE OXIDE IONICALLY CROSS-LINKED USING POLYHYDROXYL ORGANIC ANIONS. San Luis Obispo, California, May 2, 2017. FzioMed, which celebrates 21 years in business this year has received a new  patent, US 9,636,434. Methods for manufacturing ionically cross-linked compositions of carboxypolysaccharides, polyalkylene oxides,polyhydroxyl organic anions, optionally divalent cations and aqueous media are also …

Read More

Visit FzioMed at these Conferences in 2017

Meeting Name Dates    Location Global Congress on Hysteroscopy 5/2 - 5/5/2017 Barcelona, Spain FESSH 6/21 – 6/24/2017 Budapest, Hungary Eurospine 10/11 – 10/13/2017 Dublin, Ireland NASS 10/25 – 10/28/2017 Orlando, FL AAGL 11/12 – 11/16/2017 Washington, DC

Read More

Visit FzioMed at these Conferences in 2016

Mar 3 - 5 AAOS Orlando, FL Apr 6 - 8 ISASS Las Vegas, NV May 16 - 20 Spineweek 2016 Singapore Jun 22 - 25 FESSH Santander, Spain Oct 2 - 5 ESGE Brussels, Belgium Oct 5 - 7 Eurospine Berlin, Germany Oct 26 - 28 NASS Boston, MA Nov 14 - 18 AAGL …

Read More

FzioMed Patent US 9,161,987 B2 Carboxymethylcellulose/Polyethylene Glycol Compositions for Medical Uses.

SAN LUIS OBISPO, California, November 2nd 2015. FzioMed, Inc., which recently celebrated 19 years in the medical device business, has received a new patent, US 9,161,987 B2, for crosslinked compositions of carboxymethylcellulose (CMC) and polyethylene glycol (PEG) for medical uses.  The crosslinking technology provides devices that can be made with a variety of viscoelastic properties, to …

Read More

FzioMed Announces Sale of 400,000th Unit of Oxiplex

SAN LUIS OBISPO, California – July 7th, 2015 - FzioMed, Inc. (www.fziomed.com) announced that it has shipped the 400,000th unit of Oxiplex® gel.  Oxiplex is approved outside the United States in 70 countries and is distributed under the brand names Oxiplex®, Oxiplex®/SP and MediShield™. Oxiplex is an absorbable gel that is applied to spinal nerve …

Read More

Visit FzioMed at these Conferences in 2015

Jun 17 - 20 XX FESSH Congress Federation of European Societies for Surgery of the Hand XX FESSH Congress 17-20 June 2015 Milan, Italy 18th of June, 13.00h – Green Room N.3 FZIOMED SYMPOSIUM THE PREVENTION AND TREATMENT OF T/N ADHESIONS  IN HAND SURGERY STATE OF THE ART Chairmen: Michele Riccio, Gian Carlo Caruso Adhesion …

Read More

FzioMed Inc announces new patent issuance in the European Union.

SAN LUIS OBISPO, California—July 21st, 2014—FzioMed, Inc., a manufacturer and marketer of synthetic biomaterials is pleased to announce the issuance of a new patent in Europe, ‘Chemically Activated Carboxypolysaccharides and Uses’. This invention relates to derivatized carboxypolysaccharides (CPS) and their uses in gels and films incorporating polyethylene oxide (PEO) for drug delivery, and for hemostatic …

Read More

FzioMed, Inc. Announces Postponement of Dispute Resolution Panel for Oxiplex PMA

SAN LUIS OBISPO, California—May 28th, 2014— FzioMed, Inc. today announced it has agreed with the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) to postpone the Dispute Resolution Panel for its Oxiplex PMA; the meeting was previously scheduled for June 10.  The postponement was agreed between the parties …

Read More